The acyl-CoA binding protein/diazepam binding inhibitor (ACBP/DBI) is an evolutionary conserved intracellular protein that binds C14-C22 acyl-CoA esters with very high affinity. ACBP is thought to act as an acyl-CoA transporter, and in vitro analyses have indicated that ACBP can transport acyl-CoA esters between different enzymatic systems. However, little is known about the in vivo function in mammalian cells. We have generated mice with targeted disruption of ACBP (ACBP-/-). These mice are viable and fertile and develop normally. However, around weaning the ACBP-/- mice show decreased growth rate and increased levels of plasma cholesterol combined with hepatic accumulation of triglycerides and cholesteryl esters. We show by microarray analysis that the liver of ACBP-/- mice displays a significantly delayed induction of target genes of the sterol regulatory element binding protein (SREBP) family, around the weaning period. As a result, the hepatic de novo cholesterogenesis is significantly decreased at weaning. The delayed induction of SREBP target genes around weaning is caused by a compromised processing and decreased expression of SREBP precursors leading to reduced binding of SREBP to target sites in chromatin. In conclusion, lack of ACBP causes elevated levels of plasma and hepatic lipids during weaning, which interferes with the normal metabolic adaptation to weaning by delaying induction of the lipogenic gene programs in the liver.
|Publication date||12. Jan 2011|
|Number of pages||1|
|Publication status||Published - 12. Jan 2011|
|Event||Keystone Symposia: Type 2 Diabetes, Insulin Resistance and Metabolic Dysfunction - Keystone, Keystone, Colorado, United States|
Duration: 12. Jan 2011 → 17. Jan 2011
|Conference||Keystone Symposia: Type 2 Diabetes, Insulin Resistance and Metabolic Dysfunction|
|Period||12/01/2011 → 17/01/2011|